Science service company Thermo Fisher Scientific reported on Monday the availability of the new CE-IVD marked COVID-19 test, called the TaqPath COVID-19 Fast PCR Combo Kit 2.0, to produce accurate results even as the virus that causes COVID-19 continues to mutate.
The company added that the TaqPath COVID-19 Fast PCR Combo Kit 2.0. expands its range of high-precision tests for the detection of active SARS-CoV-2 infections. The kit uses an advanced assay design that compensates for current and emerging variants by using a total of eight targets in three genomic regions of the virus.
According to the company, the TaqPath COVID-19 Fast PCR Combo Kit 2.0 test evaluates raw saliva directly with a processing time of two hours to enable widespread, high-frequency testing.
Thermo Fisher Scientific added that its first generation TaqPath COVID-19 CE-IVD RT PCR Kit and TaqPath COVID-19 Combo Kit, each using a different assay design, received the first CE-IVD certification and US FDA's Emergency Use Authorization from the US in March 2020.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial